Oral Micronized Progesterone Side Effects: Incidence Rates Across Trials

What the FDA Label Says About Prometrium Adverse Events

The FDA-approved prescribing information for Prometrium is the starting reference for any incidence discussion. The label reports data from a 875-patient postmenopausal study in which OMP 200 mg/day was added to conjugated equine estrogen (CEE) 0.625 mg/day for 12 days per cycle. Somnolence/fatigue occurred in 27% of the OMP+CEE group vs. 18% in the CEE-only group, and dizziness was reported in 24% vs. 15%, respectively. [1]

Sedation: The Signature Effect

The sedative profile of OMP stems from progesterone's conversion to allopregnanolone, a neurosteroid that potentiates GABA-A receptors. This mechanism is dose-dependent. At 300 mg/night, somnolence rates exceed those seen at 100 mg by a clinically meaningful margin, though head-to-head dose-comparison data within a single trial are limited.

Clinicians at HealthRX routinely counsel patients to take OMP at bedtime specifically because the sedative peak aligns with sleep onset, turning a side effect into a therapeutic benefit for perimenopausal insomnia.

Dizziness and Coordination Effects

Dizziness incidence in the FDA label cohort reached 24% with OMP vs. 15% with placebo-equivalent (CEE alone). Falls risk in older postmenopausal women is a real downstream concern. The prescribing information explicitly warns against driving or operating heavy machinery until individual response is known. [1]

PEPI Trial Data: The Landmark Comparative Dataset

The Postmenopausal Estrogen/Progestin Interventions (PEPI) trial (N=875, 3-year follow-up) remains the most-cited head-to-head comparison of OMP against medroxyprogesterone acetate (MPA). Published in JAMA in 1995, PEPI randomized postmenopausal women aged 45 to 64 to five arms: placebo, CEE alone, CEE+MPA cyclic, CEE+MPA continuous, and CEE+OMP cyclic. [2]

Endometrial Safety Rates

Endometrial hyperplasia (a proxy for inadequate progestogen protection) was seen in 62% of the CEE-alone arm over 3 years vs. 1 to 3% in OMP and MPA arms. This finding established OMP's adequacy for endometrial protection and drove its adoption as an alternative to synthetic progestins. [2]

Bleeding and Breast Tenderness

In PEPI, breast discomfort was reported in approximately 21% of the CEE+OMP cyclic arm. Vaginal spotting and breakthrough bleeding affected roughly 35% of women in cyclic OMP arms during the first year, declining to approximately 15% by year 3 as the endometrium atrophied. Irregular bleeding is the most common reason women request dose adjustments in practice.

Lipid and Cardiovascular Adverse Signals

PEPI found that OMP preserved CEE's favorable HDL-cholesterol effect better than MPA: HDL increased by 5.6 mg/dL in the CEE+OMP arm vs. 1.6 mg/dL in CEE+MPA continuous (JAMA 1995). [2] This metabolic difference is not merely cosmetic; it underlies the working hypothesis that OMP carries a lower arterial risk than MPA, though randomized cardiovascular outcome data specific to OMP are limited.

WHI and MPA vs. OMP: What the Data Allow Us to Infer

The Women's Health Initiative (WHI) used MPA, not OMP, so its adverse event data (increased breast cancer, coronary events, stroke, pulmonary embolism) do not directly translate. The WHI publication in NEJM (2002, N=16,608) reported hazard ratios of 1.26 for breast cancer and 2.13 for pulmonary embolism with CEE+MPA vs. Placebo. [3]

Why OMP May Differ

Observational studies suggest OMP does not carry the same thrombotic or breast cancer signal. The E3N French cohort (N=80,377, published in Breast Cancer Research and Treatment) found no significant increase in breast cancer risk with CEE plus OMP (RR 1.00, 95% CI 0.83 to 1.22) compared with RR 1.69 (1.50 to 1.91) for CEE plus synthetic progestins. [4] These observational data cannot establish causality but are consistent with OMP's different receptor-binding and metabolic profile.

Thromboembolism Risk Signals

A nested case-control study from the same E3N cohort found that transdermal estradiol combined with OMP was not associated with increased venous thromboembolism risk (OR 0.7, 95% CI 0.3 to 1.9), while oral estrogen plus synthetic progestin was associated with a 4-fold increase. Published in Circulation (2007). [5] Clinicians should note these are observational findings, not randomized trial results.

Somnolence Mechanism and Incidence by Dose

Allopregnanolone, the primary neuroactive metabolite of progesterone, has a half-life of roughly 2 to 5 hours after oral administration. Peak serum levels occur 1 to 3 hours post-dose. This pharmacokinetic window explains why evening dosing is standard practice and why morning dosing generates disproportionate complaints about daytime sedation. [6]

Dose-Response for Sedation

In a pharmacodynamic study of 12 healthy postmenopausal volunteers, 300 mg OMP produced greater saccadic eye-movement slowing (a validated sedation biomarker) than 100 mg, with effects detectable for up to 6 hours post-dose. This dose-response relationship suggests that women requiring lower doses (e.g., 100 mg for luteal-phase support) face meaningfully less sedation than those on 300 mg for endometrial protection. Refer to the NIH pharmacology resource for allopregnanolone for receptor-binding details. [7]

Tolerance Over Time

Most patients who persist past the first 4 to 6 weeks report reduced sedation. The Prometrium FDA label does not provide formal tolerance data, but prescriber experience and the mechanistic literature suggest tachyphylaxis to GABA-A potentiation occurs. [1]

Mood and Psychiatric Adverse Events

Progesterone's neuroactive metabolites cut both ways. At therapeutic doses, allopregnanolone may improve anxiety and sleep. At supratherapeutic levels or during withdrawal, some women experience irritability, depressive symptoms, or mood lability.

FAERS Signal: Depression and Suicidal Ideation

A search of the FDA Adverse Event Reporting System (FAERS) database identifies depression and mood disturbances among the top 20 reported adverse events for Prometrium, though reporting rates do not imply causation and selection bias in spontaneous reporting is substantial. [8] Suicidal ideation appears in FAERS but at low absolute counts; the FDA label includes a general warning for patients with depression history.

Premenstrual Dysphoric Disorder Parallel

Women with a history of premenstrual dysphoric disorder (PMDD) or severe PMS may be paradoxically more sensitive to allopregnanolone's effects. A study in Psychoneuroendocrinology (PMID 8658950) found that women with PMDD showed an adverse behavioral response to allopregnanolone administration that was not seen in controls. [9] This suggests pre-treatment psychiatric screening is warranted.

Breast Effects: Tenderness, Density, and Cancer Risk

Tenderness Incidence

Across the PEPI trial and the FDA label cohort, breast tenderness incidence with OMP ranges from 16% to 27% in combined HRT arms. The mechanism is estrogen-driven ductal stimulation modulated but not eliminated by progestogen opposition. Tenderness typically peaks in the first 3 months and declines with continued use or dose adjustment.

Mammographic Density

Mammographic density is a risk factor for breast cancer and a confounder of screening sensitivity. A randomized trial comparing CEE+OMP vs. CEE+MPA found that OMP produced significantly less mammographic density increase at 2 years than MPA (P<0.05), suggesting a potentially lower impact on screening performance. [10]

Cancer Risk Data

As noted above, the E3N cohort found no significant breast cancer excess with OMP. The British Million Women Study (Lancet 2003, N=1,084,110) evaluated combined HRT broadly but did not disaggregate OMP from synthetic progestins in the primary analysis, limiting direct inference. [11]

Cardiovascular and Metabolic Adverse Events

Blood Pressure

OMP does not appear to raise blood pressure. The Prometrium label lists hypertension in the adverse events table but at rates comparable to placebo in the label trial. [1] In contrast, synthetic progestins like norethindrone acetate carry androgenic effects that may blunt the blood-pressure benefits of estrogen.

Glucose Metabolism

Unlike MPA, OMP does not appear to worsen insulin sensitivity. A crossover trial published in Fertility and Sterility (PMID 11255173) found that OMP had no significant effect on fasting glucose or insulin resistance indices in postmenopausal women, while MPA increased insulin area-under-curve. [12] Clinicians managing patients with prediabetes or type 2 diabetes may prefer OMP on this basis.

Lipid Effects

The PEPI data (discussed above) showed OMP's favorable HDL effect. LDL was not adversely affected. Triglyceride levels were not significantly changed. These metabolic advantages do not eliminate cardiovascular risk but are relevant when selecting a progestogen for a patient with dyslipidemia.

Vaginal Bleeding and Endometrial Adverse Events

Breakthrough Bleeding Rates

Cyclic OMP regimens (typically 200 mg/day for 12 to 14 days per cycle) produce scheduled withdrawal bleeding in most women during the first year. Unscheduled bleeding affects 30 to 40% of users in year one, declining to 10 to 15% by year three according to PEPI data. [2] Continuous combined regimens (100 mg/day every day) produce less scheduled bleeding but more unpredictable spotting in the early months.

Endometrial Hyperplasia and Cancer

The PEPI trial confirmed that OMP 200 mg/day for 12 days per month was sufficient to prevent CEE-induced endometrial hyperplasia, with hyperplasia rates of approximately 2% vs. 62% in the CEE-alone arm over 3 years. [2] No cases of endometrial cancer were attributed to OMP in PEPI. The FDA label requires that women with an intact uterus receive adequate progestogen opposition, and OMP at approved doses satisfies that requirement. [1]

Allergic and Hypersensitivity Reactions

Prometrium capsules are formulated in peanut oil. Women with peanut allergy are contraindicated from using Prometrium, and the FDA label carries a boxed warning equivalent for this population. [1] Anaphylaxis cases appear in FAERS, though absolute numbers are small given the millions of prescriptions dispensed annually.

Progesterone Hypersensitivity Syndrome

Progesterone hypersensitivity (autoimmune progesterone dermatitis) is a rare condition in which endogenous or exogenous progesterone triggers cyclic allergic reactions including urticaria, eczema, and rarely anaphylaxis. Case reports appear in PubMed (e.g., PMID 22424232). [13] Incidence is not well-quantified but is considered rare (<1 in 10,000 users in clinical estimates).

Drug Interactions Affecting the Adverse Event Profile

CYP3A4 Interactions

OMP is metabolized primarily by CYP3A4 and CYP1A2. Strong CYP3A4 inhibitors (e.g., ketoconazole, ritonavir) may raise OMP plasma levels and intensify sedative and other dose-dependent effects. Strong inducers (e.g., rifampin, carbamazepine) may reduce progesterone exposure below therapeutic thresholds. The FDA label advises caution but does not specify dose adjustments. [1]

CNS Depressants

Combining OMP with benzodiazepines, opioids, or other CNS depressants produces additive sedation. This interaction is pharmacodynamic, not pharmacokinetic, and is independent of CYP status. Clinicians should review the full medication list before prescribing OMP to patients already using sleep aids or anxiolytics.

Rare and Post-Market Adverse Events

FAERS Categories Beyond the Label

Beyond the label-listed adverse events, FAERS case reports for Prometrium include: [8]

• Jaundice and cholestatic liver injury (rare; mechanism uncertain)
• Peripheral neuropathy (very rare; causality unconfirmed)
• Visual disturbances (rare; possible CNS mechanism)
• Pulmonary embolism (rare; lower signal than with synthetic progestins)

None of these post-market categories have sufficient case counts to generate reliable incidence estimates. The standard caveat for FAERS data applies: reporting is voluntary, denominators are unknown, and confounding by indication is substantial.

Progesterone and Breast Cancer: Residual Uncertainty

The International Agency for Research on Cancer (IARC) classified combined postmenopausal HRT as Group 1 carcinogen in 2005, based largely on WHI and other MPA data. [14] Whether OMP-containing regimens share this classification remains debated. Ongoing observational data from European cohorts continue to suggest a lower risk, but no randomized trial powered for breast cancer outcomes has used OMP as the comparator arm.

Comparing Adverse Event Rates: OMP vs. MPA vs. Synthetic Progestins

| Adverse Event | OMP (approx.) | MPA (approx.) | Source | |---|---|---|---| | Somnolence/fatigue | 27 to 34% | 18 to 22% | FDA label, PEPI [1][2] | | Dizziness | 15 to 24% | 10 to 14% | FDA label [1] | | Breast tenderness | 16 to 27% | 20 to 30% | PEPI, label [1][2] | | Breakthrough bleeding (yr 1) | 30 to 40% | 25 to 35% | PEPI [2] | | HDL reduction | None (favorable) | Attenuates HDL gain | PEPI [2] | | Insulin resistance worsening | None detected | Detected | Fert Steril [12] | | Mammographic density increase | Lower | Higher | PMID 19299824 [10] | | VTE signal (observational) | Not elevated | Elevated (oral) | Circulation [5] |

The trade-off is clear: OMP produces more sedation and dizziness than MPA, but carries fewer metabolic, thrombotic, and mammographic density concerns.

Monitoring and Dose Adjustment Guidance

The Endocrine Society's 2015 guidelines on menopausal hormone therapy recommend individualized progestogen selection based on patient risk profile, tolerability, and preference. [15] For women troubled by OMP sedation, options include:

1. Shifting the entire dose to bedtime (if not already doing so).
2. Reducing the dose from 200 mg to 100 mg nightly and reassessing endometrial protection with annual ultrasound.
3. Switching to a progestogen-containing IUD (levonorgestrel IUD) for local endometrial protection without systemic sedation.
4. Considering vaginal progesterone if the indication is luteal-phase support rather than systemic HRT.

The Endocrine Society guideline states: "Micronized progesterone and dydrogesterone may be associated with a better safety and tolerability profile than older synthetic progestins." [15]

Specific Populations: Pregnancy, Liver Disease, and Older Adults

Pregnancy Use

OMP is used off-label for luteal-phase support in assisted reproduction and to reduce preterm birth risk in women with short cervical length. The NEJM trial by Fonseca et al. (2007, N=250) found vaginal progesterone reduced preterm birth by 44.2% in high-risk singleton pregnancies, but adverse events in pregnancy are dominated by vaginal irritation rather than sedation. [16] Oral OMP in pregnancy produces higher allopregnanolone levels and theoretical fetal sedation concerns that have not been resolved in controlled trials.

Hepatic Impairment

Progesterone undergoes extensive first-pass hepatic metabolism. Women with active liver disease or cholestasis of pregnancy should avoid OMP. The FDA label lists liver dysfunction as a contraindication. [1]

Older Adults (Age 65+)

Sedation and dizziness-related fall risk are amplified in women over 65. The American Geriatrics Society Beers Criteria (2023 update) lists oral estrogen and progestins as potentially inappropriate medications in older adults primarily because of cancer risk, but sedation risk from OMP warrants additional caution. [17] Starting at 100 mg rather than 200 mg in this age group is a reasonable clinical adjustment.